Latest news with #7MM
Globe and Mail
31-07-2025
- Business
- Globe and Mail
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034 as New Clinical Trials and Targeted Therapies Reshape Care
Merkel Cell Carcinoma Market Forecast, combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM. The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among healthcare professionals contributing to earlier diagnosis, increasing chronic UV exposure, and the emergence of innovative therapies such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals / AgonOx), KT 253 (Kymera Therapeutics) and others. DelveInsight's latest report, ' Merkel Cell Carcinoma Market Insight, Epidemiology, and Market Forecast,' combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan is expected to grow at a CAGR of 8.7% from USD 411 million between 2023 to 2034 Among the 7MM, the US market represented 44% of the total market size in 2023. Other major markets, EU4 and the UK, accounted for approximately 54%. Among the EU4 and the UK, Germany held the largest Merkel Cell Carcinoma market share, followed by France. Download the report to understand which factors are driving the Merkel Cell Carcinoma therapeutic market @ Merkel Cell Carcinoma Market Trends. The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by Total Merkel Cell Carcinoma Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM. According to DelveInsight's analysis, there were approximately 9000 incident cases of MCC in the 7MM. Among them, the United States accounted for nearly 37% of the cases in 2023. Furthermore, in the EU4 and the UK, approximately 80% of the total reported cases are associated with MCPyV, while 20% are linked to UV damage, indicating that MCPyV is the primary causative factor. Discover evolving trends in Merkel Cell Carcinoma patient pool forecasts @ Merkel Cell Carcinoma Epidemiology Analysis Recent Developments: In July 2025, the National Comprehensive Cancer Network published updated guidelines for MCC treatment with several important changes, including ctDNA monitoring, Radiation timing, Hypo-fractionated radiation, and others. In June 2025, the FDA lifted a manufacturing-related partial clinical hold on the phase 3 accelerated approval trial for immune agonist IFx-2.0. The trial evaluates IFx-2.0 as adjunctive therapy versus placebo with pembrolizumab in frontline treatment for patients with advanced or metastatic MCC. In May 2025, a new clinical trial (NCT06940440) began evaluating the innate immune agonist IFx-Hu2.0 in patients with noncutaneous MCC of unknown primary. In January 2025, 225Ac-SSO110, a somatostatin receptor 2 (SST2) antagonist for targeted radionuclide cancer treatments of MCC developed by Ariceum Therapeutics, received clearance for a Phase 1/2 trial (SANTANA-225) and is expected to begin enrolling patients in the first quarter of 2025. In April 2025, a multicenter study of 1,049 Merkel Cell Carcinoma patients found that radiation within eight weeks of diagnosis improved survival and reduced disease progression risk by 36%. Surgical margins of 1-2 cm led to better outcomes. At five years, 83% of patients were alive and 64% had no cancer progression, highlighting the importance of timely treatment and appropriate surgery. The Delveinsight report also discusses current diagnosis and treatment strategies for Merkel Cell Carcinoma. Existing drugs for MCC treatment include KEYTRUDA (Merck), ZYNYZ (Incyte Corporation/MacroGenics), and BAVENCIO (Merck KGaA). The treatment depends on the disease stage and individual factors, primarily involving surgery as the first-line therapy, often combined with radiation or chemotherapy. Chemotherapy, once a key treatment for advanced Merkel Cell Carcinoma, now plays a reduced role due to limited long-term effectiveness. Cytotoxic chemotherapy, while it has been effective for metastatic MCC, often leads to significant side effects by affecting normal cells. DelveInsight's analysis reveals that several companies are launching clinical trials to investigate new MCC treatment options or to improve existing ones. The Merkel Cell Carcinoma clinical development pipeline includes drugs such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals/AgonOx), and KT 253 (Kymera Therapeutics), among others. Unlock which emerging Merkel Cell Carcinoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Merkel Cell Carcinoma Market Insights. Another pipeline drug, IFx-2.0 (developed by TuHURA Biosciences), is also set for phase III trial with KEYTRUDA for advanced MCC in 2025. These developments highlight the momentum in the MCC treatment landscape. MCC presents significant challenges, especially in diagnosis, due to its rarity, unclear origin, and similarity to other skin lesions. DelveInsight's leading oncology consultant commented, 'As MCCs are frequently misdiagnosed, biomarkers are needed to improve their detection to prompt biopsy to confirm diagnosis by histology and immunohistochemistry, respectively.' This highlights the potential of more precise and sensitive emerging diagnostic methods to revolutionize Merkel Cell Carcinoma treatment, driving market growth. Table of Contents 1. Key Insights 2. Report Introduction 3. Merkel Cell Carcinoma Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Merkel Cell Carcinoma Background and Overview 7. Merkel Cell Carcinoma Epidemiology and Market Methodology 8. Epidemiology and Merkel Cell Carcinoma Patient Population 9. Merkel Cell Carcinoma Patient Journey 10. Merkel Cell Carcinoma Marketed Therapies 11. Merkel Cell Carcinoma Emerging Drug Profiles 12. MCC: Market Analysis 13. Key Opinion Leaders' Views 14. Merkel Cell Carcinoma Unmet Needs 15. Merkel Cell Carcinoma SWOT Analysis 16. Merkel Cell Carcinoma Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Merkel Cell Carcinoma Pipeline Insight Merkel Cell Carcinoma Pipeline Insight provides comprehensive insights about the Merkel Cell Carcinoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Merkel Cell Carcinoma companies, including ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, and Sensei Biotherapeutics, among others. About DelveInsight DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Yahoo
26-07-2025
- Business
- Yahoo
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity
The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launch of emerging therapies such as Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), and others, heightened UV exposure, advancements in diagnostic techniques, and lifestyle changes. New York, USA, July 22, 2025 (GLOBE NEWSWIRE) -- Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launch of emerging therapies such as Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), and others, heightened UV exposure, advancements in diagnostic techniques, and lifestyle changes. DelveInsight's Melanoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging melanoma drugs, market share of individual therapies, and current and forecasted Melanoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Melanoma Market Report According to DelveInsight's analysis, the total melanoma market size is expected to grow positively by 2034. The United States accounts for the largest market size of melanoma, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. In 2024, the total number of incident cases of melanoma was approximately 105K in the US. The trend indicates that melanoma occurs more frequently in males than in females, and around 20% of cases eventually progress to advanced stages (stage III/IV), involving unresectable or distant metastatic disease. Prominent companies, including Istari Oncology, Philogen, Georgiamune, Diakonos Oncology, Immatics Biotechnologies, Replimune, BMS, Ascentage Pharma, Erasca, Krystal Biotech, IDEAYA Biosciences, Novartis, HUYA Bioscience, Regeneron Pharmaceuticals, and others, are actively working on innovative melanoma drugs. Some of the key melanoma therapies in the pipeline include Lerapolturev, Nidlegy, GIM-531, DOC-1021, IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, APG-115, Naporafenib (ERAS-254), KB707, Darovasertib (IDE196), HBI-8000, Fianlimab, and others. These novel melanoma therapies are anticipated to enter the melanoma market in the forecast period and are expected to change the market. In May 2025, Immatics announced the presentation of expanded data from the ongoing Phase Ib clinical trial evaluating IMA203 in heavily pretreated patients with metastatic melanoma In April 2025, IDEAYA Biosciences announced a successful FDA Type D meeting on the Phase III registrational trial design that would assess the safety and efficacy of darovasertib for potential regulatory approval as neoadjuvant therapy for primary uveal melanoma. Discover which melanoma medications are expected to grab the market share @ Melanoma Market Report Melanoma Overview Melanoma is a type of skin cancer that originates in melanocytes, the pigment-producing cells responsible for giving skin its color. While it is less common than other skin cancers, melanoma is significantly more aggressive and has a higher risk of spreading to other parts of the body if not detected early. It can occur anywhere on the body but is most frequently found on areas exposed to the sun, such as the back, legs, arms, and face. The primary cause of melanoma is ultraviolet radiation from sunlight or artificial sources like tanning beds, which can damage the DNA in skin cells. Individuals with fair skin, a history of sunburns, a large number of moles, or a family history of melanoma are at higher risk. Genetic mutations, such as in the BRAF gene, also play a significant role in the development of melanoma in certain cases. Symptoms of melanoma often begin with changes in the appearance of a mole or pigmented area. Warning signs include asymmetry, irregular borders, color variation, a diameter larger than 6 mm, and evolving shape or size, summarized by the ABCDE rule. Itching, bleeding, or the appearance of a new mole can also be concerning signs. Diagnosis typically involves a thorough skin examination followed by a biopsy of any suspicious lesion. If melanoma is confirmed, further tests such as sentinel lymph node biopsy, imaging scans (CT, MRI, or PET), and blood work may be conducted to determine the stage and whether the cancer has spread. Early diagnosis is critical, as it significantly improves the prognosis and expands treatment Epidemiology Segmentation The melanoma epidemiology section provides insights into the historical and current melanoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The melanoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Incident Cases of Melanoma Stage-specific Incident Cases of Melanoma Mutation-specific Incident Cases of Melanoma Line-wise Treated Cases of Melanoma Download the report to understand which factors are driving melanoma epidemiology trends @ Melanoma Treatment Algorithm Melanoma Treatment Market There remains a substantial unmet need for effective treatment options in melanoma patients who are resistant to, unsuitable for, or unresponsive to standard therapies like checkpoint inhibitors or BRAF/MEK-targeted treatments. The FDA has approved several therapies for melanoma, including AMTAGVI (lifileucel, Iovance Biotherapeutics), OPDUALAG (nivolumab + relatlimab, Bristol Myers Squibb), KEYTRUDA (pembrolizumab, Merck), OPDIVO (nivolumab, BMS), KIMMTRAK (tebentafusp-tebn, Immunocore), YERVOY (ipilimumab, BMS), TECENTRIQ (atezolizumab, Roche), among others. AMTAGVI, from Iovance Biotherapeutics, became the first FDA-approved, personalized, one-time T cell therapy in February 2024. It is intended for adults with unresectable or metastatic melanoma who have previously been treated with PD-1 inhibitors, and for those with BRAF V600 mutations, after BRAF inhibitor ± MEK inhibitor therapy. That same year, Iovance submitted a Marketing Authorization Application (MAA) for lifileucel to the EMA in June (validated in August) and to the UK's MHRA in October. In June 2025, Iovance announced that the final results from the Phase II C-144-01 trial of AMTAGVI in advanced melanoma patients were published in the Journal of Clinical Oncology and presented at the 2025 ASCO Annual Meeting. Bristol Myers Squibb's OPDUALAG combines nivolumab, a PD-1 inhibitor, with relatlimab, a LAG-3 inhibitor, and is indicated for the treatment of unresectable or metastatic melanoma. The FDA approved it in March 2022 for adults and children aged 12 and above. However, in February 2025, BMS reported that the Phase III RELATIVITY-098 trial did not achieve its primary endpoint of recurrence-free survival (RFS) in the adjuvant setting for completely resected stage III–IV melanoma, although the safety profile remained consistent with existing data on the combination. KEYTRUDA and OPDIVO both demonstrate strong efficacy in treating melanoma, though OPDIVO has gained greater commercial traction through effective combination regimens and broader clinical use. Despite metastatic melanoma often being incurable, the emergence of advanced treatments such as immune checkpoint inhibitors and targeted therapies has markedly improved survival and quality of life, signaling a significant evolution in the standard of care. Learn more about the melanoma treatment options @ Melanoma Treatment Guidelines Melanoma Emerging Drugs and Companies Some of the products in the pipeline include Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), RP1 (vusolimogene oderparepvec) plus nivolumab (Replimune and BMS), APG-115 (Ascentage Pharma), Naporafenib (ERAS-254) (Erasca), KB707 (Krystal Biotech), Darovasertib (IDE196) (IDEAYA Biosciences and Novartis), HBI-8000 (HUYA Bioscience and BMS), Fianlimab (Regeneron Pharmaceuticals), and others. IMA203 is a TCR T-cell therapy that targets the Preferentially Expressed Antigen in Melanoma (PRAME). It's designed to identify an intracellular PRAME-derived peptide displayed on the surface of cells by HLA-A*02:01, triggering a strong and specific anti-tumor immune response. Encouraging Phase Ib results, along with PRAME's high expression rate in melanoma (~90–95%), support IMA203's therapeutic promise. The therapy is currently under investigation in the SUPRAME Phase III trial (NCT06743126) for previously treated advanced or metastatic cutaneous melanoma, and its Phase Ib expansion now includes uveal melanoma. According to the company's 2024 Annual Report, interim analysis for IMA203 is expected in Q1 2026, with final Phase III results in Q4 2026. A Biologics License Application (BLA) submission is planned for Q1 2027, aiming for a market launch in Q3 2027. RP1 is a herpes simplex virus-based therapy modified with a fusogenic protein (GALV-GP R) and GM-CSF to enhance tumor cell destruction, increase immunogenic cell death, and promote a systemic anti-tumor immune response. The FDA has awarded Breakthrough Therapy Designation (BTD) for RP1 in combination with nivolumab for adults with advanced melanoma that has progressed after anti-PD1 treatment. In June 2025, Replimune shared updated results from the IGNYTE study (RP1 + nivolumab in anti-PD1-refractory melanoma) at the 2025 ASCO Annual Meeting. Darovasertib (IDE196) is a potent, selective PKC inhibitor in clinical development. PKC lies downstream of the GNAQ and GNA11 pathways. Darovasertib is currently in a Phase III trial for primary non-metastatic uveal melanoma, a Phase II/III (DAR-UM-2) study for HLA-A2-negative metastatic uveal melanoma (MUM), and other Phase II trials in ocular melanoma. The company expects results from the pivotal DAR-UM-2 trial in first-line HLA-A2-negative MUM by late 2025. In March 2025, the FDA granted BTD to darovasertib for neoadjuvant treatment of primary uveal melanoma patients recommended for enucleation. The anticipated launch of these emerging melanoma therapies are poised to transform the Melanoma market landscape in the coming years. As these cutting-edge melanoma therapies continue to mature and gain regulatory approval, they are expected to reshape the melanoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for melanoma, visit @ Melanoma Management Melanoma Market Dynamics The melanoma market dynamics are anticipated to change in the coming years. Drugs like OPDIVO and KEYTRUDA, particularly in combination with ipilimumab, have significantly improved overall survival and achieved durable response rates (~30–40%) in metastatic melanoma; however, the limited long-term efficacy in many patients highlights the urgent need for effective second-line therapies and continued innovation. With nearly 50% of melanoma patients harboring BRAF mutations, targeted therapy has become a viable option, while molecular profiling enables patient stratification even in refractory settings for clinical trials and off-label interventions. Moreover, targeting underrepresented melanoma subtypes such as uveal, mucosal, and acral presents opportunities for market expansion and accelerated regulatory pathways, given the high unmet need and paucity of existing therapies. Furthermore, many potential therapies are being investigated for the treatment of melanoma, and it is safe to predict that the treatment space will significantly impact the melanoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the melanoma market in the 7MM. However, several factors may impede the growth of the melanoma market. Moreover, melanoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the melanoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the melanoma market growth. Melanoma Report Metrics Details Study Period 2020–2034 Melanoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Melanoma Companies Istari Oncology, Philogen, Georgiamune, Diakonos Oncology, Immatics Biotechnologies, Replimune, BMS, Ascentage Pharma, Erasca, Krystal Biotech, IDEAYA Biosciences, Novartis, HUYA Bioscience, Regeneron Pharmaceuticals, and others Key Melanoma Therapies Lerapolturev, Nidlegy, GIM-531, DOC-1021, IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, APG-115, Naporafenib (ERAS-254), KB707, Darovasertib (IDE196), HBI-8000, Fianlimab, and others Scope of the Melanoma Market Report Melanoma Therapeutic Assessment: Melanoma current marketed and emerging therapies Melanoma Market Dynamics: Conjoint Analysis of Emerging Melanoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Melanoma Market Access and Reimbursement Discover more about melanoma drugs in development @ Melanoma Clinical Trials Table of Contents 1. Melanoma Market Key Insights 2. Melanoma Market Report Introduction 3. Melanoma Market Overview at a Glance 4. Melanoma Market Executive Summary 5. Disease Background and Overview 6. Melanoma Treatment and Management 7. Melanoma Epidemiology and Patient Population 8. Patient Journey 9. Melanoma Marketed Drugs 10. Melanoma Emerging Drugs 11. Seven Major Melanoma Market Analysis 12. Melanoma Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis Related Reports Melanoma Pipeline Melanoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key melanoma companies, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, among others. Ocular Melanoma Market Ocular Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ocular melanoma companies, including Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline PLC, Amgen Inc., among others. Uveal Melanoma Market Uveal Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveal melanoma companies, including Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, among others. Metastatic Melanoma Market Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic melanoma companies, including Cancer Insight LLC, Elios Therapeutics LLC, Evaxion Biotech A/S, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, InxMed (Shanghai) Co. Ltd., Aivita Biomedical Inc., Hoffmann-La Roche, Idera Pharmaceuticals, Iovance Biotherapeutics Inc., Eisai Inc., Biocad, Myrexis Inc., Pain Therapeutics, Altor BioScience, among others. Refractory Metastatic Melanoma Market Refractory Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory metastatic melanoma companies, including BioNTech SE, Y-mAbs Therapeutics, Seagen Inc., among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter CONTACT: Contact Us Shruti Thakur info@ +14699457679 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Health
- Yahoo
Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of XOLAIR in Adults, PALFORZIA in Toddlers and Expected Entry of Viaskin Peanut Patches
The evolving peanut allergy treatment market landscape features clinical trials led by DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual Immunotherapy-Tablet), InnoUp Farma (INP20), Allergy Therapeutics (VLP Peanut), Intrommune Therapeutics (INT301), Regeneron Pharmaceuticals (Linvoseltamab + Dupilumab), and others. LAS VEGAS, July 16, 2025 /PRNewswire/ -- DelveInsight's Peanut Allergy Market Insights report includes a comprehensive understanding of current treatment practices, peanut allergy emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Peanut Allergy Market Report According to DelveInsight's analysis, the market size for peanut allergy was found to be USD 400 million in the 7MM in 2024, and is expected to witness a drastic growth owing to increased usage of approved therapies, expected entry of novel emerging therapies, and a slight increase in diagnosis over time. In 2024, the US reported approximately ˜5,129,500 prevalent cases of peanut allergy, yet only about 50% of affected individuals received treatment, highlighting a significant gap in patient care and therapy adoption. PALFORZIA has seen limited uptake due to modest clinical benefits over standard peanut avoidance, with minimal impact on reducing allergic reactions Following PALFORZIA's approval in the US, Roche and Novartis' XOLAIR was approved in early 2024, adding a new option to the food allergy treatment landscape, including peanut allergy. Although XOLAIR could be a lucrative option for adult patients with minimal needle phobia, XOLAIR's high annual cost may pose a barrier to affordability and patient access, potentially hindering its broader adoption. By 2034, among all the therapies, the highest revenue is expected to be generated by VIASKIN in the 7MM. Around 70% of treated patients choose desensitization, reflecting strong demand, creatinga clear opportunity for safer, easier alternatives like Viaskin to improve adoption and long-term protection Based on DelveInsight's assessment in 2024, the 7MM had 9.8 million diagnosed prevalent cases of peanut allergy. Mild-to-moderate peanut allergy contributed majorly t in 2024 within the 7MM. Our trend estimates suggest a consistent rise in these cases during the study period (2020–2034). Leading peanut allergy companies developing emerging therapies, such as DBV Technologies, Novartis, Aravax, ALK-Abello, InnoUp Farma, Intrommune Therapeutics, and others, are developing novel peanut allergy drugs that can be available in the peanut allergy market in the coming years. The promising peanut allergy therapies in the pipeline include Viaskin (DBV712) peanut patch, Remibrutinib (LOU064), PVX108 (AVX-201), Sublingual Immunotherapy (SLIT)-Tablet, INP20, INT301, and others. Discover which therapies are expected to grab the peanut allergy therapeutics market share @ Peanut Allergy Market Report Peanut Allergy Market Dynamics The peanut allergy market dynamics are expected to change in the coming years. PALFORZIA, administered orally, offers a convenient and accessible treatment option compared to traditional SC, intradermal, and epicutaneous therapies, potentially enhancing patient adherence and reducing the burden on healthcare systems; desensitization has improved peanut allergy treatment by increasing the reaction threshold, helping prevent accidental anaphylaxis and offering meaningful protection for patients and families, while the adult peanut allergy market remains an untapped opportunity, with XOLAIR as the sole approved treatment and only remibrutinib under evaluation, highlighting significant potential for growth, especially as increasing investment and partnerships in the allergy treatment space accelerate the development of novel therapies. Furthermore, potential therapies are being investigated for the treatment of peanut allergy, and it is safe to predict that the treatment space will significantly impact the peanut allergy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the peanut allergy market in the 7MM. However, several factors may impede the growth of the peanut allergy market. Notable weakness in the peanut allergy landscape is the slow uptake of PALFORZIA, underdiagnosis of mild patients, lack of approved treatment options for adult patients(except XOLAIR), with remibrutinib being the only drug currently under evaluation for the 18–55 age group. This is compounded by the limited number of active drugs in the pipeline, highlighting a gap in therapeutic innovation that restricts treatment options and hinders progress in addressing diverse patient needs. Additionally, the high annual cost of XOLAIR, ranging from USD 30,000 to USD 60,000, poses a significant threat by limiting affordability and access, thereby challenging its widespread adoption. Furthermore, inconsistent or unclear food labeling practices increase the risk of accidental exposure, complicating condition management and posing ongoing risks for individuals with peanut allergies. Moreover, peanut allergy treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the peanut allergy market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the peanut allergy market growth. Peanut Allergy Treatment Market Managing peanut allergies requires a comprehensive approach, with strict avoidance of the allergen remaining the key method for preventing severe, potentially fatal anaphylactic reactions. However, recent clinical guidelines mark a significant change in prevention strategies by recommending the early introduction of peanut-containing foods between 4 to 6 months of age, even for infants at high risk. This proactive approach has been shown to greatly reduce the chances of developing a peanut allergy, replacing the older practice of strict avoidance. While medications such as antihistamines, corticosteroids, and bronchodilators can be used during allergic reactions, it's important to note that they do not treat anaphylaxis directly. These are supportive treatments used alongside other interventions in managing anaphylactic episodes. Although allergen avoidance remains the foundation of care, innovative preventive measures are under development. One such method, oral immunotherapy, involves gradually increasing exposure to small amounts of peanut, and clinical trials have shown encouraging results. Another promising desensitization technique is epicutaneous immunotherapy, where peanut protein is applied to the skin over time to help build tolerance. This form of therapy has improved peanut allergy management by increasing the reaction threshold, lowering the risk of accidental exposure, and providing patients with added protection and confidence. Currently, PALFORZIA and XOLAIR are the only approved treatments for peanut allergy. PALFORZIA is authorized for children aged 1–3 and 4–17 years, while XOLAIR is approved for individuals aged 1 year and older. These peanut allergy therapies offer valuable options for both patients and healthcare professionals in managing peanut allergies. To know more about peanut allergy treatment options, visit @ Peanut Allergy Medication Peanut Allergy Pipeline Therapies and Key Companies A robust pipeline of emerging therapies for peanut allergy is progressing, driven by innovative treatments with diverse mechanisms of action, such as Remibrutinib (Novartis), INP20 (InnoUp Farma), SLIT tablet (ALK-Abello), INT301 (Intrommune Therapeutics), and the combination of Linvoseltamab and Dupilumab. Among these, the Viaskin Peanut Patch (DBV Technologies) stands out as a promising noninvasive option, offering ease of use and a strong safety profile, which may make it especially suitable for young children aged 1 to 7. Viaskin Peanut is an epicutaneous immunotherapy (EPIT) that delivers trace amounts of peanut protein via a skin patch to promote desensitization in allergic individuals. It has received both Fast Track and Breakthrough Therapy Designations from the US FDA. The therapy is currently being assessed in a Phase III clinical trial involving peanut-allergic children aged 4 to 7. DBV Technologies expects to share top-line data from the VITESSE trial (NCT05741476) in Q4 2025. In March 2025, DBV Technologies and the FDA aligned on key regulatory steps following written responses to a Type D IND meeting request. The FDA agreed that safety exposure data from the VITESSE Phase III trial in children aged 4–7 would be adequate to support a Biologics License Application (BLA) for this age group, potentially advancing the BLA submission to the first half of 2026. A separate BLA for children aged 1–3 is planned for the second half of 2026, contingent on the successful outcome of the COMFORT Toddlers Study. PVX108 is a next-generation immunotherapy that utilizes engineered peptides to specifically engage T cells and retrain the immune system, aiming to reverse allergic responses. It is currently in a Phase II clinical trial for children and adolescents with peanut allergies. In November 2024, Aravax established a UK subsidiary at Oxford Science Park, marking a strategic step in its global expansion in food allergy treatment. Additionally, in October 2024, the company completed patient enrollment for its Phase II study (AVX-201) evaluating PVX108. Remibrutinib is an oral, highly selective, covalent Bruton's Tyrosine Kinase (BTK) inhibitor being developed for a range of autoimmune and inflammatory conditions, including chronic spontaneous urticaria, myasthenia gravis, multiple sclerosis, food allergy, and hidradenitis suppurativa. It is currently in a Phase II clinical trial for adults with peanut allergy. These new peanut allergy therapies, which act on different molecular targets and pathways, represent encouraging alternatives to existing treatments. Their development underscores a growing emphasis on more precise and targeted strategies for managing the complexities of peanut allergy Additionally, the anticipated launch of these emerging therapies are poised to transform the peanut allergy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the peanut allergy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Discover more about peanut allergy drugs in development @ Peanut Allergy Clinical Trials Recent Developments in the Peanut Allergy Market In March 2025, DBV Technologies reached an understanding with the US FDA based on written replies to its Type D IND meeting request. The FDA concurred with DBV's proposal that safety exposure data from the VITESSE Phase III study of the Viaskin Peanut Patch in children aged 4–7 years would be sufficient to support BLA filing for this age group, thereby accelerating the anticipated timeline for BLA submission to the first half of 2026. In March 2025, the US FDA approved OMLYCLO (omalizumab-igec) as the first interchangeable biosimilar for reference XOLAIR and the first respiratory biosimilar for the treatment of moderate-to-severe persistent asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), IgE-mediated food allergy, and Chronic Spontaneous Urticaria (CSU). In March 2025, DBV Technologies announced a financing of up to USD 306.9 million (EUR 284.5 million), comprising gross proceeds of USD 125.5 million (EUR 116.3 million) to be received upon closing and up to an additional USD 181.4 million (EUR 168.2 million) in gross proceeds contingent upon the full exercise of warrants, subject to the satisfaction of specified conditions. In February 2025, Stallergenes Greer launched PALFORZIA in the US to treat toddler patients, ages 1–3 years, with a confirmed diagnosis of peanut allergy. The FDA approved the expanded indication for toddler patients (ages 1–3 years) in July 2024 based on the data from the Phase III POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study that was published in the New England Journal of Medicine Evidence in 2023. In January 2025, the European Commission approved the extension of the indication of PALFORZIA for the treatment of toddlers (ages 1–3) with a confirmed diagnosis of peanut allergy. The marketing authorization covered all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein, and Norway). In December 2024, ALK announced positive interim results from the Phase I/II clinical trial (ALLIANCE) for its investigational SLIT tablet for the treatment of peanut allergy. Peanut Allergy Overview Peanut allergy is one of the most prevalent food allergies in children and has notably increased over recent decades. It results from an abnormal immune response involving IgE antibodies directed against peanut proteins, which can cause severe and potentially life-threatening anaphylactic reactions. Beyond the immediate health dangers, this allergy significantly affects the quality of life for both patients and their families. Compared to other IgE-mediated food allergies, peanut allergy is associated with a higher incidence of anaphylaxis-related fatalities in emergencies. In individuals with this allergy, the initial exposure to peanut antigens activates Th2 cells that release cytokines, encouraging the production of IgE antibodies. These antibodies attach to Fce receptors on mast cells and basophils, sensitizing them. Upon subsequent exposure, the allergen crosslinks the IgE on these primed cells, leading to degranulation and the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This response triggers vasodilation, increased vascular permeability, and inflammation, manifesting in allergic symptoms. In addition to these biochemical processes, mechanical factors in the allergic microenvironment also influence immune activity. When diagnosing peanut and other food allergies, a detailed clinical history is essential to appropriately interpret test results. The most accurate diagnostic method is the double-blind, placebo-controlled food challenge (DBPCFC). However, skin prick testing (SPT) and measurement of specific IgE levels are commonly used first-line tools due to their speed and affordability. Peanut Allergy Epidemiology Segmentation The peanut allergy epidemiology section provides insights into the historical and current peanut allergy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The peanut allergy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Peanut Allergy Gender-specific Cases of Peanut Allergy Age-specific Cases of Peanut Allergy Severity-specific Cases of Peanut Allergy Peanut Allergy Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan]. Peanut Allergy Market CAGR 16 % Peanut Allergy Market Size in 2024 USD 400 Million Key Peanut Allergy Companies DBV Technologies, Novartis, Aravax, ALK-Abello, InnoUp Farma, Intrommune Therapeutics, Stallergenes Greer, Roche, and others Key Peanut Allergy Therapies Viaskin (DBV712) peanut patch, Remibrutinib (LOU064), PVX108 (AVX-201), Sublingual Immunotherapy (SLIT)-Tablet, INP20, INT301, PALFORZIA, XOLAIR, and others Scope of the Peanut Allergy Market Report Therapeutic Assessment: Peanut Allergy current marketed and emerging therapies Peanut Allergy Market Dynamics: Key Market Forecast Assumptions of Emerging Peanut Allergy Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Peanut Allergy Market Access and Reimbursement Download the report to understand which factors are driving peanut allergy market trends @ Peanut Allergy Treatment Market Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 Peanut Allergy Market Overview at a Glance 6.1 Market Share (%) Distribution by Therapies in 2024 in the 7MM 6.2 Market Share (%) Distribution by Therapies in 2034 in the 7MM 7 Disease Background and Overview 7.1 Introduction 7.2 Symptoms 7.3 Risk Factors 7.4 Pathophysiology of Peanut Allergy 7.5 Diagnosis 7.6 Treatment 8 Epidemiology and Patient Population 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Total Diagnosed Prevalent Cases of Peanut Allergy in the 7MM 8.4 The United States 8.5 EU4 and the UK 8.6 Japan 9 Patient Journey 10 Marketed Drugs 10.1 Key Competitors 10.2 PALFORZIA (peanut allergen powder-dnfp): Stallergenes Greer 10.3 XOLAIR (omalizumab): Roche and Novartis 11 Emerging Therapies 11.1 Key Cross Competition 11.2 Viaskin (DBV712) peanut patch: DBV Technologies 11.3 Remibrutinib (LOU064): Novartis 11.4 PVX108 (AVX-201): Aravax 11.5 Sublingual Immunotherapy (SLIT)-Tablet: ALK-Abello 12 Peanut Allergy: Seven Major Market Analysis 12.2 Market Outlook 12.3 Conjoint Analysis 12.4 Key Market Forecast Assumptions 12.5 DBV Technology: In-depth Analysis 12.6 Total Market Size of Peanut Allergy by Country in the 7MM 12.7 United States Market Size 12.8 EU4 and the UK Market Size 12.9 Japan Market Size 13 Unmet Needs 14 SWOT Analysis 15 KOL Views 16 Market Access and Reimbursement 16.1 United States 16.2 EU4 and the UK 16.3 Japan 16.4 Market Access and Reimbursement of Peanut Allergy 17 Bibliography 18 Report Methodology Related Reports Food Allergy Market Food Allergy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key food allergy companies including Stallergenes Greer, Roche, Novartis, ARS Pharmaceuticals, ALK-Abelló, Alfresa Pharma, DBV Technologies, Aquestive Therapeutics, Bryn Pharma, Aravax, RAPT Therapeutics, Allergy Therapeutics, Regeneron Pharmaceuticals, among others. Peanut Allergy Pipeline Peanut Allergy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peanut allergy companies, including Allergy Therapeutics, DBV Technologies, Novartis, Aravax, ALK-Abello, Intrommune Therapeutics, LAPIX Therapeutics, among others. Food Allergy Pipeline Food Allergy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key food allergy companies, including DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune, among others. Lactose Intolerance Market Lactose Intolerance Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lactose intolerance companies including CRitter Pharmaceuticals Inc., a2 Milk Company Ltd, VenterPharma, Eurofarma Laboratorios S.A, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakurinfo@ + Logo: View original content: SOURCE DelveInsight Business Research, LLP
Globe and Mail
16-05-2025
- Business
- Globe and Mail
Acute Myocardial Infarction Market to Evolve with Novel Therapies and Strategic Advancements by 2034
The Acute Myocardial Infarction (AMI) market is undergoing transformative change, spurred by advancements in rapid diagnostic technologies, personalized treatment approaches, and cardioprotective therapeutics. DelveInsight's latest AMI market report explores epidemiological trends and current treatment practices, along with pipeline innovations aimed at reducing infarct size and improving long-term cardiovascular outcomes. The ' Acute Myocardial Infarction Market Report ' by DelveInsight offers a robust analysis of market size, treatment algorithms, and unmet needs across the 7MM, providing stakeholders with actionable insights to navigate a highly competitive and evolving cardiovascular space. Some of the Key Facts of the Acute Myocardial Infarction Market Report: • The AMI market in the 7MM is valued at USD 1.6 billion in 2023, with expected strong growth. • In 2023, the U.S. had ~823K incident AMI cases, projected to rise by 2034. • LODOCO, FDA-approved by AGEPHA Pharma, is the first treatment targeting residual inflammatory risk in cardiovascular disease. • NSTEMI cases (~607K) outnumbered STEMI cases in the U.S. in 2023. • In March 2025, Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announced that its PMcardio STEMI AI ECG model has received Breakthrough Device Designation from the FDA. This recognition highlights PMcardio's innovation in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents, conditions that require urgent intervention. • In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FLYRCADO (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD). Flyrcado offers superior diagnostic efficacy compared to the widely used single-photon emission computed tomography (SPECT) MPI, enhancing access to PET MPI and improving accuracy, particularly in challenging cases like high BMI patients and women. • Emerging acute myocardial infarction drugs include Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others. • Leading companies in the acute myocardial infarction market include Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others. To know in detail about the acute myocardial infarction market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Acute Myocardial Infarction Market Forecast Acute Myocardial Infarction Overview Acute Myocardial Infarction (AMI) refers to the death of heart muscle tissue due to the sudden blockage of a coronary artery. Common symptoms include chest pain, shortness of breath, nausea, and sweating. Diagnosis is based on electrocardiogram (ECG) findings and cardiac biomarkers. Treatment typically involves antiplatelet and anticoagulant medications, nitrates, beta-blockers, statins, and timely reperfusion therapies. In ST-segment elevation myocardial infarction (STEMI), emergency reperfusion is achieved through fibrinolytics, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). In non-ST-segment elevation myocardial infarction (NSTEMI), PCI or CABG is also used. AMI remains a leading cause of mortality in developed nations and is classified into two main types: STEMI and NSTEMI. While unstable angina shares similarities with NSTEMI, it does not show elevated cardiac biomarkers. Get a free sample of the acute myocardial infarction market report with key insights and emerging therapies here: Acute Myocardial Infarction Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Acute Myocardial Infarction Epidemiology Segmentation: The Acute Myocardial Infarction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Total Incident Cases of AMI • Type-Specific Incident Cases of AMI • Gender-Specific Incident Cases of AMI Download the report to understand which factors are driving acute myocardial infarction epidemiology trends @ Acute Myocardial Infarction Epidemiology Forecast Acute Myocardial Infarction Drugs Uptake, and Pipeline Development Activities The acute myocardial infarction drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the acute myocardial infarction market or expected to be launched during the study period. The analysis covers the acute myocardial infarction market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the acute myocardial infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Acute Myocardial Infarction Market Strengths • Strong pipeline with innovative therapies targeting inflammation, thrombosis, and cardiac repair. • High disease burden and awareness ensure steady demand for treatment and care. Acute Myocardial Infarction Market Weaknesses • High treatment costs limit access in low- and middle-income regions. • Delayed diagnosis and limited emergency care affect outcomes in underserved areas. Scope of the Acute Myocardial Infarction Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Acute Myocardial Infarction Therapies: Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others. • Key Acute Myocardial Infarction Companies: Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others. • Acute Myocardial Infarction Therapeutic Assessment: Acute myocardial infarction, currently marketed, and acute myocardial infarction emerging therapies • Acute Myocardial Infarction Market Dynamics: Acute myocardial infarction market drivers and Acute Myocardial Infarction market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Acute Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Acute Myocardial Infarction Market Access and Reimbursement To learn more about the key players and advancements in the acute myocardial infarction treatment landscape, visit the Acute Myocardial Infarction Market Analysis Report Table of Contents 1. Acute Myocardial Infarction Market Report Introduction 2. Executive Summary for Acute Myocardial Infarction 3. SWOT analysis of Acute Myocardial Infarction 4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance 5. Acute Myocardial Infarction Market Overview at a Glance 6. Acute Myocardial Infarction Disease Background and Overview 7. Acute Myocardial Infarction Epidemiology and Patient Population 8. Country-Specific Patient Population of Acute Myocardial Infarction 9. Acute Myocardial Infarction Current Treatment and Medical Practices 10. Acute Myocardial Infarction Unmet Needs 11. Acute Myocardial Infarction Emerging Therapies 12. Acute Myocardial Infarction Market Outlook 13. Country-Wise Acute Myocardial Infarction Market Analysis (2020–2034) 14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies 15. Acute Myocardial Infarction Market Drivers 16. Acute Myocardial Infarction Market Barriers 17. Acute Myocardial Infarction Appendix 18. Acute Myocardial Infarction Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
